{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Fcelmod-agents-in-mm-t__Fv414","width":444,"version":"1.0","type":"rich","title":"Experts Discuss CELMoD Agents for Treating Multiple Myeloma","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/86952976-b928-4317-884c-2c7ba3b2ae4d/7c28848b-a1bc-4f20-b964-572e47722f36/100552-mm-celmods-ash-3000x3000.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/175f5d42-88cf-4cf8-8cbe-dfe3f119c44a\" height=\"200\" width=\"100%\" title=\"Experts Discuss CELMoD Agents for Treating Multiple Myeloma\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Listen to Jesus Berdeja, MD; Amrita Krishnan, MD, FACP; and Niels van de Donk, MD, PhD, address key questions on CELMoD agent therapy for multiple myeloma, including combination strategies, adverse event management, and where CELMoD agents may best fit within current and future treatment strategies."}